Lung Therapeutics releases details about $36M funding

Lung Therapeutics is developing two primary drugs: LTI-01 to treat loculated pleural effusion, a serious complication of pneumonia, and LTI-03 to treat idiopathic pulmonary fibrosis.

Source: bizjournals.com Health Care:Biotechnology headlines - June 5, 2019 Category: Biotechnology Authors: Will Anderson Source Type: news